Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Brief summary
Phase I trial to study the effect on the body of combining oxaliplatin with bortezomib in treating patients who have metastatic or unresectable cancer. Drugs used in chemotherapy such as oxaliplatin use different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth. Combining oxaliplatin with bortezomib may kill more cancer cells
Detailed description
OBJECTIVES: I. Determine the maximum tolerated dose and recommended phase II dose of oxaliplatin and bortezomib in patients with advanced malignancy. II. Determine the dose-limiting toxicity of this regimen in these patients. III. Determine the toxicity profile of this regimen in these patients. IV. Determine the antitumor activity of this regimen in these patients. V. Determine the pattern of neurotoxicity and its reversibility in patients responding to prolonged administration of this treatment regimen. VI. Determine whether the pharmacokinetics and pharmacodynamics of oxaliplatin or bortezomib are altered by the administration of the other agent in these patients. OUTLINE: This is a dose-escalation study. Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the maximum tolerated doses (MTDs) are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed for at least 3 months. PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 4-15 months.
Interventions
DRUGoxaliplatin
Given IV
DRUGbortezomib
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
OTHERpharmacological study
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed malignancy for which standard curative or palliative measures do not exist or are no longer effective * Metastatic or unresectable disease * No known brain metastases * Performance status - ECOG 0-2 * Performance status - Karnofsky 60-100 * More than 6 months * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin normal * AST and ALT no greater than 5 times upper limit of normal * Creatinine no greater than 1.5 mg/dL * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history of allergic reactions attributed to compounds of similar chemical or biological composition to any platinum or other study agents * No pre-existing peripheral neuropathy * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No other concurrent uncontrolled illness * Prior thalidomide allowed provided patient has no clinical neuropathy * Prior platinum or antitubulin agents allowed provided patient has no clinical neuropathy * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered * More than 3 weeks since prior radiotherapy and recovered * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent investigational or commercial agents or therapies for the malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Probability of dose escalation according to true dose limiting toxicity (DLT) rate, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 | Up to 28 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the curve (AUC) estimates | Days 1 and 15 (course 1) | Nonlinear compartmental analysis of the oxaliplatin pharmacokinetic data will be performed. |
| Pharmacodynamic assessments (20S proteasome inhibition data) | Days 1 and 15 (course 1) | Summarized by dose and time using standard descriptive statistics. Asssessments will correlate the AUC in an Emax inhibitory model. |
| Sequence of drug administration in terms of PK interaction | Days 1 and 15 (course 1) | AUC for oxaliplatin and 20-S proteasome inhibition will be calculated and compared for intra-patient variation using paired T-test. |
Countries
United States
Outcome results
None listed